

Journal Pre-proof

In vitro models for the study of liver biology and diseases – advances and limitations

Savneet Kaur, Sri Kidambi, Martí Ortega-Ribera, Le Thi Thanh Thuy, Natalia Nieto, Victoria C. Cogger, Wei-Fen Xie, Frank Tacke, Jordi Gracia-Sancho



PII: S2352-345X(22)00245-4
DOI: <https://doi.org/10.1016/j.jcmgh.2022.11.008>
Reference: JCMGH 1114

To appear in: *Cellular and Molecular Gastroenterology and Hepatology*
Accepted Date: 23 November 2022

Please cite this article as: Kaur S, Kidambi S, Ortega-Ribera M, Thanh Thuy LT, Nieto N, Cogger VC, Xie W-F, Tacke F, Gracia-Sancho J, *In vitro* models for the study of liver biology and diseases – advances and limitations, *Cellular and Molecular Gastroenterology and Hepatology* (2022), doi: <https://doi.org/10.1016/j.jcmgh.2022.11.008>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.

***In vitro* models for the study of liver biology and diseases – advances and limitations**

Short title: In vitro methods to study liver (patho)biology

Savneet Kaur^{*1}, Sri Kidambi^{*2}, Martí Ortega-Ribera^{*3}, Le Thi Thanh Thuy ^{*4}, Natalia Nieto⁵, Victoria C. Cogger⁶, Wei-Fen Xie⁷, Frank Tacke⁸, Jordi Gracia-Sancho^{9,10}

1- Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

2- Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Nebraska, USA.

3- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

4- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

5- Department of Pathology, University of Illinois at Chicago, 840 S. Wood St., Suite 130 CSN, MC 847, Chicago, IL 60612, USA.

6- Faculty of Medicine and Health, University of Sydney, Sydney 2008 Australia

7- Department of Gastroenterology, Naval Medical University, Shanghai, China.

8- Department of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, 13353 Berlin, Germany

9- Liver Vascular Biology, IDIBAPS Biomedical Research Institute & CIBEREHD, Barcelona, Spain.

10- Department of Visceral Surgery and Medicine, Department for Biomedical Research, Inselspital, University of Berne, Switzerland.

* denotes co-first authors.

Corresponding author

Jordi Gracia-Sancho, PhD. IDIBAPS Biomedical Research Institute – Hospital Clínic de Barcelona. Rosselló 149, 08036, Barcelona, Spain. jgracia@recerca.clinic.cat

Financial support

S.K. is supported by the ASEAN grant (CRD/2019/000120) from Department of Science and Technology, India.

S.K. is supported, in whole or in part, by NIH grants 1R01AA027189-01A1, P20 GM104320 (to the Nebraska Center for the Prevention of Obesity Diseases Pilot Grant), P20 GM113126 (to the Nebraska Center for Integrated Biomolecular Communication), and Nebraska Research Initiative-Systems Grant.

L.T.T.T. received support from the Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS-22K08083, 22H03061) and a Grant for Research Program on Hepatitis from the Japan Agency for Medical Research and Development (AMED- JP22fk0210107).

N.N. received funding from the US Public Health Service Grant R01 DK111677 from the National Institute of Diabetes and Digestive and Kidney Diseases, R01AA025907 from the National Institute on Alcohol Abuse and Alcoholism, and US Veterans Administration Grant I01BX005093 from the Biomedical Laboratory Research & Development.

V.C.C is supported by the McKnight Philanthropic Bequest and National Health and Medical Research Council

W-F.X. is supported by the National Natural Science Foundation of China (82030021).

F.T. is supported by the German Research Foundation (DFG SFB/TRR 296 and CRC1382, Project-ID 403224013) and the German Ministry of Education and Research (BMBF DEEP-HCC consortium).

J.G.-S. is supported by the Instituto de Salud Carlos III (FIS PI20/00220, co-funded by the European Union), the CIBEREHD, the Swiss National Science Funds (320030_189252), the Novartis Foundation for Medical-Biological Research and the Foundation Suisse Contre le Cancer du Foie.

Disclosures

FT's lab received research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva.

JG-S' lab received research funding from Gilead, Inventiva, Conatus, Surrozen, GAT Tx and BrudyLab.

S.K., S.K., M.O-R., L. T.T.T, N.N, V.C.C. and W.-F.X have nothing to disclose.

Word count: 4980

Abbreviations

iPSCs	induced pluripotent stem cells
NAFLD	non-alcoholic fatty liver disease
NASH	non-alcoholic steatohepatitis
LoC	liver-on-a-chip
CLD	chronic liver disease
HSCs	hepatic stellate cells
2D	two-dimensional
HBV	hepatitis B virus

LSECs	liver sinusoidal endothelial cells
ECM	extracellular matrix
3D	three-dimensional
PLA	polylactic acid
PLGA	poly (lactic-co-glycolic acid)
BEASTS	bio-engineered adhesive siloxane substrate with tunable stiffness
PDMS	polydimethyl siloxane
KLF2	krüppel-like factor 2
sc-RNA Seq	single cell RNA sequencing
PCLS	precision cut liver slices
HCC	hepatocellular carcinoma
PNPLA3	patatin like phospholipase domain containing 3
MS	mass spectrometry
PDGF β	platelet derived growth factor beta
ECs	endothelial cells

Abstract

In vitro models of liver (patho)physiology, new technologies and experimental approaches are progressing rapidly. Based on cell lines, induced pluripotent stem cells (iPSCs) or primary cells derived from mouse or human liver as well as whole tissue (slices), such *in vitro* single- and multi-cellular models, including complex microfluidic organ-on-a-chip systems, provide tools to functionally understand mechanisms of liver health and disease. The International Society of Hepatic Sinusoidal Research (ISHSR) commissioned this working group to review the currently available *in vitro* liver models and describe the advantages and disadvantages of each in the context of evaluating their use for the study of liver functionality, disease modelling, therapeutic discovery and clinical applicability.

Keywords

Hepatic sinusoid, mechanobiology, omics, bioengineering, cirrhosis, NAFLD, NASH

1- Introduction

Liver disease represents one of the leading causes of death worldwide, and the incidence of some pathologies, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver cancer, continues to rise ¹. Despite years of research, liver diseases still have limited treatment options in the clinic. This paucity of treatments is partly explained by the limitations of traditional *in vitro* tools and animal models that do not accurately mimic the clinical pathophysiology of diseases and have a low accuracy for drug discovery purposes. Indeed, several studies have shown that traditional cell culture methodologies do not reflect the complexity of a human liver *in vivo* and thus cannot predict drug sensitivity. In contrast, animal models differ in biology compared to human pathologies, which explains why promising therapies tested in animal models often fail when tested in humans and, unfortunately, the field of hepatology has numerous recent examples of failures in clinical phases ². With the advent of precision medicine, which offers much hope for individual patient outcomes, there is increased demand for robust and patient-specific tools to better improve our understanding and treatment of complex and multifactorial diseases such as liver diseases. Advances in vascular biology, microfluidics, and bioengineering have led to the development of sophisticated *in vitro* models that could fill this gap (Figure 1). In addition, omics techniques provide further insight to pre-clinical research in hepatology. In this review, we discuss the benefits and limitations of advanced *in vitro* research techniques that are presently being applied to the study of liver diseases and further critique how these tools may provide an insight into the prediction of patients' responses to a therapy.

2- Liver-on-chip & microfluidic devices

During the XXI century, the development of biology-inspired devices aimed at mimicking the sinusoidal niche integrating microfluidics led to the rapidly evolving liver-on-a-chip (LoC) technology ³. The design of these *in vitro* liver-resembling tools, which have been

extensively reviewed in ⁴ and is out of the scope of the present review, are inspired in sinusoidal cell biology, architecture and hemodynamics but materialized under each research teams' eyes in terms of appearance, size, fabrication procedures, costs, and microfluidics integration, leading to significant variation in the finalized product.

Latest advances in the field include chronic liver disease-specific devices, LoC models designed to study key pathophysiological processes in the development of liver disease and to understand the interconnection with other organs-on-chip to better depict liver functions and systemic implications (Figure 2). Multi-organ chips, for instance, liver-, adipose- and gut-on-a-chip connected, may be particularly suitable to understand organ-crosstalk in chronic liver disease (CLD) such as NAFLD/NASH or cholangiopathies ⁵.

In the recent years, disease-focused LoC devices mimicking some of the landmark etiological characteristics of CLD have been developed. Fat accumulation in hepatocytes, occurring in NAFLD/NASH, has been represented in LoC under the combination of glucose and free fatty acids (usually a 2:1 ratio of oleic and palmitic acid) ⁶. Antifibrotic compounds such as obeticholic acid, elafibranor ⁷, pioglitazone or metformin ^{8,9} showed promising results in reducing lipid droplets in these *in vitro* settings. Indeed, the anti-NASH agent lanifibranor efficiently reduced hepatocytic lipid accumulation ¹⁰, and improved human hepatocyte and hepatic stellate cells (HSCs) phenotype ¹¹ in a LoC model but not in two-dimensional (2D) cell cultures, supporting the specific value of multicellular LoC devices over traditional mono-cell cultures. Alcohol-associated liver disease has been addressed in several publications focusing on its impact in sinusoidal cell biology during development ¹² or recovery from alcohol (abstinence) either with perfused spheroid ¹³ or layered cultures ¹⁴. Importantly, Ortega-Prieto et al ¹⁵ developed a model for hepatitis B virus (HBV) long-term infection in primary human hepatocytes which recapitulates virus-host interactions and its associated immune effectors. LoC using primary cells isolated using standardized protocols from pre-clinical models of CLD and from patients have also been developed ^{16,17}. These

specialized LoC settings may widen the current knowledge on disease dynamics and provide potential applicability as *in vitro* preclinical models for drug screening.

Even though LoC complexity has outstandingly increased since the initial models/prototypes, the intricacy of the whole liver is still underrepresented. In this regard, several scientists brought the attention and focused their studies into specific processes or structures. For example: the essential features of the bile duct containing primary mouse cholangiocytes ¹⁸, the unique vasculature organization of the liver ¹⁹, the sinusoidal zonation within LoC devices ²⁰, neutrophil recruitment and interaction with liver sinusoidal endothelial cells (LSECs) after lipopolysaccharide stimulation ²¹ or drug metabolism and toxicity ²² are now embedded in available LoC systems.

Moreover, CLD has been extensively reported as a systemic syndrome with major extrahepatic implications ²³. Therefore, the combination of LoC devices has now evolved to the extent that disease specific models are being combined with others such as intestine, brain, kidney ^{24–26} or even metastasis niche-on-chip models ²⁷ to recreate body-on-chip structures to further study gut-liver-brain axis, systemic drug clearance or exosome communication between the liver and the tumor microenvironment. However, alongside these advances in multi-organ and etiology-centered approaches, a lack of consensus in cellular sources and mechanobiological cues within the various LoC models remain as unsolved challenges in the field.

3- Liver scaffolds, matrices & other substrates

A key component for the engineering of *in vitro* liver models is the development of appropriate scaffold/matrix that recapitulates the hepatic microenvironment well-enough to result in realistic functional cells. Several factors affect the efficiency of a scaffold as a support for liver cell growth and function including porosity, pore size, biomechanical properties, and the scaffold design. To simulate the microenvironment of natural extracellular matrix (ECM), substrate design and biomechanical properties are of great

significance; hence, bioinspired and biomimetic approaches have been explored to model the healthy or damaged liver (Figure 3). Double layers of collagen have been used for years as a well-established 2D *in vitro* model for sandwich cultures of hepatocytes²⁸. Recent studies have identified, and characterized, the hepatic matrisome comprising ECM signatures beyond collagen that can potentially provide matrix for *in vitro* systems to study liver diseases^{29,30}.

Scaffolds have been fabricated using natural polymers such as gelatin, elastin, silk fibroin, chitosan, chitin, fibrin, and fibrinogen or synthetic polymers like polylactic acid (PLA), poly(glycolic acid), polyhydroxyalkanoate, and poly (lactic-co-glycolic acid) (PLGA)³¹. Modified versions of biomaterials such as collagen incorporated PLGA have resulted in enhancement of hepatocyte survival and functions likely due to an increase in the bioactivity of the newly developed scaffolds^{32,33}. Similarly, natural polymers such as silk fibroin have been modified with arginyl-glycyl-aspartic acid or RGD (an integrin-based cell adhesion motif), that has been reported to support the growth of functional hepatocyte clusters³⁴. The modification with RGD may also support attachment of LSECs, known as endothelialization of materials³⁵. Efficient spheroid cultures of hepatocytes have been reported on highly porous hydrogel scaffolds composed of alginate and galactosylated chitosan³⁶. Additionally, synthetic polymer thin films-based scaffolds allow organized hepatocytes culture and patterned co-culture of hepatocytes with non-parenchymal cells^{37–39}. Recent interest in mechanical signaling has led to the development of scaffolds that can recreate liver stiffness in physiological and pathological conditions. In this context, heparin hydrogel has been developed to modulate stiffness and has demonstrated that hepatocytes cultured on a softer heparin hydrogel (10 kPa) retained five times higher levels of albumin production compared to those on a stiffer heparin gel (110 kPa) after 5 days⁴⁰. Primary hepatocytes grown on modified polyacrylamide gels with cell adhesive ligands are shown to reduce albumin production and impair hepatocyte function with increasing stiffness^{41,42}. Chang and co-

workers used polyacrylamide gels to tune the substrate stiffness and demonstrated that fibrotic levels of stiffness significantly inhibit hepatocyte-specific functions in part through the inhibition of the hepatocyte nuclear factor 4 α transcriptional network mediated via the Rho/Rho-associated protein kinase pathway ⁴³. An innovative platform named BEASTS (Bio-Engineered Adhesive Siloxane substrate with Tunable Stiffness) based on a polydimethyl siloxane (PDMS) substrate in combination with polyelectrolyte multilayer film-coating technology was developed to engineer mechanically tunable substrates mimicking physiologic and pathologic liver stiffness ^{44–48}. More recently, 3D bioprinting has emerged for precise spatial positioning of both cells and biomaterials or bioinks such as alginate together in 3D complex geometries and providing mechanical support ^{49,50}. Nguyen et al have bioprinted hepatocytes and non-parenchymal cells in 3D architecture and developed models of drug induced liver injury ⁵¹. Recent studies have printed liver cells along with a liver decellularized ECM bioink creating an environment for maximal cellular function ^{52–54}. With 3D bioprinting, vascular and biliary fluidic channels have also been successfully created in the LoC device format ⁵³. 3D bioprinting of spheroids and organoids represent the next level of technological advancement for creating the highly complex liver architecture ⁵⁵.

4- Liver spheroids and organoids

As described above, over the last century, 2D cell cultures have been used as common *in vitro* models to study cellular responses to stimulations and allowing the construction of low-cost, simple and well-accepted models of liver disease. However, they do not precisely reflect the true physiological state of cells *in vivo* due to the absence of structural, mechanical, and biochemical cues, as well as the interaction between cells and extracellular matrices ⁵⁶. To overcome this limitation, novel 3D cell culture platforms including liver spheroid and organoid cultures are being created to better mimic the *in vivo* conditions ^{57–61}. 3D spheroids are produced via self-assembly, in which mono-dispersed cells form 3D microtissues called multi-cellular spheroids, and mimic natural

processes that occur during embryogenesis, morphogenesis and organogenesis ⁶². 3D organoids derive from either pluripotent stem cells, neonatal tissue stem cells or adult stem cells/adult progenitors, in which cells spontaneously self-organize into properly differentiated functional cell types and progenitors, resembling their *in vivo* counterparts and recapitulating at least some functions of the organ ⁶³.

In the field of studying liver diseases, recent innovation of hepatic 3D spheroids also offer a promising application via combination of 3D printing based techniques and HepG2 liver spheroid culture models to develop *in situ* quantitative evaluation and high-throughput monitoring of drug-induced hepatotoxicity ⁶⁴. HepG2 cell-laden hydrogel constructs were 3D printed in the shape of a cross on the mini-9-well plate which showed the of HepG2 liver spheroids embedded in the gelatin-alginate hydrogel. On the 6th day of culture, HepG2 liver spheroids exposed to varying concentrations of troglitazone and nefazodone were used to predict hepatotoxicity. This model provided a promising tool for screening and characterization of hepatotoxicity in a 3D spheroid-embedded hydrogel system that more closely resembles conditions *in vivo*.

In 2013, Takebe et al. first described the *in vitro* generation of 3D liver buds organoids from human iPSCs derived hepatic endoderm cells co-cultured with endothelial and mesenchymal lineages ⁵⁹. Interestingly, when these liver buds were ectopic transplanted at various sites including the cranium, subrenal capsule, distal-, and proximal-mesentery in immunodeficient mice, they were able to rescue the drug induced lethal liver failure model ^{61,65}. These studies have provided a promising new approach to study regenerative medicine and to translate these techniques for treating patients with end-stage liver failure ⁶⁵. Furthermore, single cell RNA sequencing (scRNAseq) data from human liver bud organoids revealed several aspects of heterotypic interlineage communication and organ development ⁶⁶. Interestingly, Shinozawa et al. reported a simple, robust, and high-throughput human liver organoid system to measure bile transport activity by live fluorescent imaging with large-scale screening and multiplexed

readouts. By using this system, the study analyzed the pathology of drug induced liver injury and provided the possibility to assess varying drug susceptibilities based on individual polymorphism at organoid resolution ⁶⁷. These approaches are undergoing rapid developments, allowing to establish human organoids from adult/fetal human liver or pluripotent stem cells and modelling different liver diseases ^{68,69,70,71}. Different types of liver organoid models from mice, humans, dogs, cats are now available for several monogenic liver diseases such as Alagille syndrome, cystic fibrosis, primary sclerosing cholangitis, Wilsons disease, HBV infection, steatosis or liver cancer amongst others ^{72–78}. The generation of organoids from adult patient liver tissues also retains the genetic background of the individual patient thus creating patient-specific disease models and enabling in-depth investigations of pathogenesis mechanisms underlying genetic diseases and cancer. In conclusion, induced liver buds and liver organoids provide a platform for cell-based therapy, liver disease models, drug screening which satisfy the demands of both basic and translational biomedical research.

5- Tissue-based approaches

Precision cut liver slices (PCLS) are a native liver-like *ex vivo* model with intact intercellular and cell-matrix interactions ⁷⁹. PCLS systems use *ex vivo* liver explants with a well-defined thickness and in comparison, to the primary hepatocytes that are short-lived and lose much of their function in culture, PCLS cultures have been maintained for 15 days under optimal conditions. Hepatocytes in slices retain their membrane and intracellular polarization, in contrast to isolated hepatocytes, which lose their anatomical polarity after isolation. PCLS cultures have been established both from murine and human livers (Figure 3).

Human tissue for PCLS are obtained from explanted, resected, or non-transplantable tissues from liver tumor patients undergoing transplantation or liver resection. Liver slices can also be obtained from patients with severe fibrosis and cirrhosis undergoing transplantation. These are usually obtained using Krumdieck (now 'Alabama') tissue

slicer to make liver slices with their diametric from 5-8 mm^{79,80}, their thickness at 250-350 μm ⁸¹. These slices are then cultured with William's' E medium in regular tissue plates either in static, dynamic or bioreactor-based culture systems. In static conditions, PCLS cultures have a shorter lifespan (24-48 hours) due to hypoxia and increased cell death. To minimize hypoxic death, strategies such as the use of synthetic oxygen carriers, rocking or shaking cultures or perfusion bioreactors have been employed to provide better perfusion of oxygen and media components^{82,83}. One study has reported PCLS *ex vivo* cultures with sustained viability for over a two-week period on a rocking platform⁸⁴. Through microarray profiling of purified individual cells, this study illustrated that all liver cells undergo changes in their gene expression profiles until day 4 of PCLS cultures, however these changes seem to be stabilized from day 4 until day 15.

Recently, a study has cultured PCLS on a bioreactor platform at a flow rate of about 18 $\mu\text{L}/\text{sec}$, which imparted functional longevity to the system for about 6 days without any hepatocellular stress and fibrogenesis⁸³. Using this system, the study also successfully modelled *ex vivo* liver fibrogenesis using transforming growth factor $\beta 1$ and platelet-derived growth factor (PDGF β) stimulation. In another similar culture platform, primary hepatocytes or liver stem cells have been cultured on ECM discs developed from a decellularized porcine⁸⁵ or rat liver⁸⁶.

Human PCLS cultures have proven indispensable for modelling of liver diseases and to the study of transport, metabolism, biotransformation of drugs, toxins and xenobiotics in both normal and diseased conditions⁸⁷⁻⁸⁹. They have also been employed to study ischemia/reperfusion damage in rodents and to evaluate the efficacy, specificity and toxicity of virus-mediated gene therapy agents^{80,90}.

With improved technological advancements and culture longevity, PCLS cultures of patient-specific tissues offers enormous potential for the characterization of patient-specific liver cellular heterogeneity and for the screening of novel anti-fibrotic and anti-tumorigenic drugs.

6- Mimicking the sinusoidal mechanobiology *in vitro*

LSECs, the second most abundant cell type in the liver, are a key players in maintaining hepatic homeostasis ⁹¹. Importantly, LSECs differ from classical vasculature endothelium, as they lack an organized basement membrane and have cytoplasm that is penetrated by open fenestrae, making the hepatic microvascular endothelium discontinuous ⁹². LSECs behavior is largely regulated by shear stress and mechanical stretch induced by blood perfusion and liver microenvironment stiffness changes derived from deposition of ECM ^{93–96}. The effect of these varying mechanical cues on LSECs is particularly interesting, however, this has not been extensively explored until recently. Employing *in vitro* culture models of LSECs with microfluidic setups revealed the effects of shear stress-derived effects. In a pioneering work from the Sessa and Groszmann labs, authors demonstrated that LSECs respond to increasing shear stress in the microenvironment by increasing nitric oxide (NO) synthesis ⁹⁷. Subsequent work defined the upstream signaling pathways, including the induction of the transcription factor Krüppel-like factor 2, in both healthy and cirrhotic LSECs ⁹⁸. A recent study by Shah and co-workers further elucidated the role of the mechano-sensitive pathways in LSECs which drive recruitment of circulating blood cells contributing to portal hypertension and fibrogenesis ⁹⁹. Using a Flexcell device, cyclic biaxial stretch on murine LSEC was modelled, and demonstrated transcriptional up-regulation of several chemotactic cytokines (CXCL1, CXCL2, and CCL2), neutrophil-extracellular traps activation from the recruited neutrophils and microthrombi formation contributing to fibrosis. More recently, a LoC device with microfluidics was used to mimic physiological and pathological pressures on primary LSECs culture ¹⁰⁰. Transcriptomic analysis revealed the detrimental effect of increased pressure on LSECs phenotype and allowed to identify LSEC-derived pressure-related genes as non-invasive biomarkers for portal hypertension. Altogether these data demonstrate that mechanical cues can cause

angiocrine and phenotypic changes in LSECs, leading to rapid alteration of HSCs phenotype and fibrogenesis ¹⁰¹.

In fibrotic livers, microvasculature remodeling contributes to increased ECM deposition and consequent raise in the intrahepatic vascular resistance ⁹². Wells and colleagues demonstrated that increased stiffness induced activation of HSCs ¹⁰². Juin and co-workers showed that increased ECM matrix rigidity increased the number of podosomes (actin-rich structures involved in motility and proteolysis) formed in LSECs suggesting that the cells responded to mechanical stress, however effect on LSEC function was not explored ¹⁰³. Impairment of hepatocyte and stellate cell function in response to high stiffness has been previously described in the literature ^{41,43,102,104}. In the context of liver-specific endothelial cells, a recent publication demonstrated that LSECs also dedifferentiate in high stiffness conditions, losing their capacity of producing vasoactive mediators such as NO and becoming capillarized as shown by the loss of their characteristic fenestrae. Interestingly, authors point out the tension between the cytoskeleton and the nuclear shape as process transducing the stiffness sensing into phenotypical responses in all sinusoidal cells ¹⁰⁵. Importantly, this last study also demonstrated that cirrhotic liver cells improve their phenotype when cultured in a healthy (non-stiff) environment, suggesting potential new avenues of therapy development. In an unpublished work, Kidambi and co-workers confirmed that LSECs are responsive to stiffness resulting in rapid capillarization (loss in fenestrae), loss of hyaluronic acid endocytosis, and higher cell adhesion molecules ⁴⁶.

These advanced *in vitro* experiments point to an interesting and underexplored area of the role of mechanical stimuli on sinusoidal biology during physiological and pathological conditions. The key to unlocking the potential therapeutic avenues for sinusoidal dysfunction from these *in vitro* findings will be to integrate the data with *in vivo* functions.

7- “omics” for the study of liver cells

Advances in omics methods have led to discoveries in liver biology and pathology at the cellular, tissue and system levels. These methods have also facilitated holistic insight into CLD in the clinical setting, and are generating non-invasive diagnostic modalities for the distinct stages of liver diseases. This multi-omics approach consists of tracing the flow of information from transcriptomics, proteomics, metabolomics, scRNA-seq, single nucleus analysis, and interactomics. The key findings of these techniques are summarized herein.

Transcriptomics refers to the quantitative assessment of all coding and non-coding RNA transcripts and reflects cellular transcriptional activity. Transcriptomic profiling has resulted in various predictive modalities involving gene expression parameters, targeted measurements and miRNA panels with increased functionality in different chronic liver diseases ^{106,107}. Several studies have identified miR-122 as a potential diagnostic biomarker for chronic liver diseases. Most of them have shown that miR-122 alone or in combination with other miRNAs (e.g. miR-1290, miR-27, miR-192, miR-34, miR-99a) can accurately predict the presence of NAFLD or NASH, but they all perform inadequately when trying to differentiate NAFLD from NASH ^{108–110}. A recent study carried out a comprehensive transcriptomic analysis of primary LSECs during the progression of cirrhosis in which specific molecular signatures, novel biomarkers and therapeutic targets associated with LSECs were delineated ¹¹¹.

Proteomics refers to the investigation of “proteome” - all proteins expressed by a cell. Several studies have investigated the hepatic proteome alone or in combination with the blood proteome, both in animal models or in humans with chronic liver diseases, aiming to answer fundamental pathophysiological questions ^{112,113}. Mann and co-workers assessed the levels and cellular distribution of 6000 liver proteins and 16000 phosphopeptides in the liver of mice developing hepatic steatosis due to high fat diet. This work produced important fundamental information about the reorganization of organelles, lipid accumulation and cellular dysfunction that occurs with nutrient overload

¹¹². Xue and co-workers identified almost 220 proteins that are significantly different in patients with NAFLD compared to obese metabolically healthy individuals. The proteins that were identified to be increased in CLD were those involved in peroxisome proliferator-activate receptor-signaling and ECM-receptor interactions whereas the ones that were reduced were mainly localized in mitochondria and involved with oxidative phosphorylation ¹¹³. Expanding on complications of the disease, the proteome of specific cells has also been examined. Helm and co-workers compared the proteome of hepatocytes monoculture and hepatocytes in organotypic rat liver models ¹¹⁴, and showed that when in a 3D liver model the predominant proteomic phenotype supports fatty acid metabolism and when hepatocytes are cultured in monoculture the proteome shifts to favor glucose metabolism. Additionally, they observed an increase in structural and migratory proteins (signaling hepatocyte dedifferentiation), in hepatocytes monoculture, highlighting the need for cell-cell and cell-ECM interactions for maintenance of functional hepatocytes. He and co-workers carried out a proteomic analysis between normal and dedifferentiated LSECs ¹¹⁵. Dedifferentiation and loss of fenestrae in LSECs precedes the onset of fibrosis and is considered a crucial event in the pathology of liver diseases ^{92,116,117}. A comparison of the normal and dedifferentiated LSECs showed that in dedifferentiated LSECs the most enriched functional categories of proteins were those related to nucleotide, organic acid metabolism, oxidative stress, small molecular and lipid metabolism, cell death regulation and endocytosis while those down-regulated by dedifferentiation were transcription regulation, actin cytoskeleton reorganization, cell migration, immune system process, ribosome biogenesis, apoptotic process, angiogenesis, glycerophospholipid metabolism and cellular lipid metabolism.

Metabolomics refers to the investigation of small molecules and metabolic products, such as amino acids, fatty acids and carbohydrates. A growing number of studies have begun to study liver specific metabolomics in the context of develop and disease using both primary cells and cell culture models. Ishida and co-workers analyzed and compared

metabolites in fetal and adult hepatocytes from human donors ¹¹⁸. They identified 211 metabolites in the hepatocytes. Specifically, the metabolites in the glycolysis/glyconeogenesis pathway, tricarboxylic acid cycle and urea cycle were lower in fetal hepatocytes than in adult hepatocytes. Tang and co-workers used nuclear magnetic resonance based metabolomics to investigate the metabolic alterations in hepatocytes caused by HBV infection ¹¹⁹. They showed that HBV infection contributed to hepatocellular carcinoma (HCC) by upregulation of the glutamine-fructose-6-phosphate amidotransferase 1 -activated hexosamine biosynthesis and choline kinase alpha -activated phosphatidylcholine biosynthesis. Cheng and co-workers demonstrated using NMR-based metabolomic approach that HBV protein (HBx) disrupted the metabolism of glucose, lipids, and amino acids, especially nucleic acids ¹²⁰. Sanyal and co-workers performed metabolic profiling on Huh7 cells with patatin like phospholipase domain containing 3 (PNPLA3) siRNA silencing and overexpression using gas chromatography – mass spectrometry (MS) and liquid chromatography-MS metabolic profiling of Huh7 cells to investigate its role in HCC ¹²¹. Silencing of PNPLA3 gene resulted in decrease in amino acid metabolism, suggestive of a catabolic response with extensive protein breakdown. Among the lipids, there was an increase in the levels of myoinositol, cysteine sulfinic acid, polyunsaturated fatty acids, lysolipids, and sphingolipids. Overexpression of PNPLA3 mirrored metabolic changes in the opposite direction with an increase in the levels of cholesterol and lactic acid with a shift to anaerobic metabolism. Some of the metabolic signatures associated with the presence of PNPLA3 risk allele such as high cholesterol levels, very low density lipoproteins levels etc have also been associated with cardiovascular disease in patients with NAFLD ¹²². These, and other studies¹²³, explain how the use of omics approaches could help to unravel novel phenotype and pathogenesis mechanisms associated with the presence of genetic polymorphisms in complex human liver diseases.

Single-cell, -nuclei transcriptomics using next-generation transcript sequencing (sc/snRNA-seq) is now emerging as a powerful tool to profile cell-to-cell variability on a genomic scale with broad implications for both basic and clinical research ¹²⁴. In a mouse model of liver fibrosis induced by carbon tetrachloride (CCl₄), Krenkel *et al* used freshly isolated HSCs for scRNA-seq and found that activation of HSCs and their trans-differentiation towards collagen-secreting myofibroblasts split into heterogeneous populations, characterized by α SMA, collagens, or immunological markers, while resting HSCs formed a homogenous population characterized by high PDGFR expression ¹²⁵. A similar scRNA-seq study using CCl₄ to induce advanced liver cirrhosis identified 6 clusters of liver endothelial cells (EC) populations including 3 clusters of LSECs which associated with zone-specific transcriptomic changes, 2 clusters of vascular ECs, and 1 cluster of lymphatic ECs ¹²⁶. Hepatotoxicity induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin also demonstrated the diversity of liver cells through the identification of 11 subtypes following pericentral, midzonal, and periportal hepatocyte subpopulations by snRNA-seq whose technique was more feasible than scRNA-seq in terms of application to frozen samples ¹²⁷. Recently, scRNA-seq was utilized to characterize mouse embryos at day E7.5 to E10.5, and Lotto *et al* provided a comprehensive atlas liver cell lineage detailing divergence of vascular and sinusoidal endothelia, hepatoblast specification, and the emergence of a distinct, migratory hepatomesenchymal cell type ¹²⁸. The most developed scRNA-seq data set is likely that established key immune cell populations in the liver, particularly from mouse models of NAFLD/NASH ¹²⁹. A series of elegant studies using scRNA-seq has provided unprecedentedly granular insights into hepatic immune cell heterogeneity, revealing striking alterations, particularly in myeloid cells and macrophages in liver diseases ^{130–134}, and into related extrahepatic compartments such as bone marrow ¹³⁵ or adipose tissue ¹³⁶.

Regarding the cellular landscape of the human liver, scRNA-seq has also revealed the physiological heterogeneity of human liver cells ^{137,138}, the fibrotic niche of human liver

cirrhosis including the identification of pathogenic subpopulations of TREM2+CD9+ macrophages, atypical chemokine receptor 1+ and plasmalemma vesicle associated protein+ ECs and PDGFR α + collagen-producing myofibroblasts ¹³⁹, and the immune microenvironment in the context of HCC ¹⁴⁰. Although sc/snRNA-seq remains an expensive and time consuming technique that requires skilled bioinformatics support, it is a valuable tool to characterize liver function and gene expression dynamics during liver disease, as well as to identify prognostic markers or signatures, and to facilitate discovery of new therapeutic targets ¹⁴¹. A key challenge for all mentioned omics techniques is accurate data integration. For instance, the most granular insight into single-cell transcriptomes by sc/snRNA-seq techniques comes at the expense of isolating the cells (or nuclei) out of their cellular context ¹⁴¹; therefore, spatially resolved modalities (e.g. multiplex immunostaining, spatial transcriptomics, imaging mass cytometry) are needed to complement these findings ¹⁴². This has been convincingly demonstrated for immune cell populations, in which not only the immune cell phenotype (or single-cell transcriptome) but also their location within the hepatic microenvironment determines their most likely function during liver diseases ¹⁴³.

8- Conclusions and future directions

As described above, in recent years there has been a great advance in the availability and utility of *in vitro* systems for the study of the pathophysiology of the liver. Today we have a wide range of possibilities to better understand the behavior of cells and tissues in the laboratory, which combine harmoniously with those observations obtained in animal models. Although progress in the field of translational hepatology is evident, we must continue working to create more complete, reliable and cost-effective systems of human liver diseases. In the following lines we summarize some of the avenues of work that we should develop through collaborative, multidisciplinary work combining the academic and private sectors.

Liver-on-a-chip systems, which already reflect the multicellularity of the liver, should be improved by incorporating biomechanical stimuli typical of the disease under study, such as a specific matrix or sinusoidal pressure, and potentially the relevant immune cells. In addition, the incorporation of biochemical or biological parameter sensors would be of great help for real time cellular analysis in response to new drugs.

The great potential of 3D liver systems, which currently mostly use matrices of natural origin, has the great advantage of simulating the ECM of the human liver but, at the same time, complicates its standardization and global use. The development and validation of matrices with defined composition, perhaps including the most abundant components in adequate ratios, could assist with expanding their use. Similarly, experimental variables that mimic the biomechanics of the sinusoid (shear stress, pressure, stiffness...) should also be standardized, thus facilitating the comparison of results from different research groups.

The use of PCLS allows an understanding the hepatic response to new compounds but only for a limited period of time. It would be very beneficial to improve the viable incubation time, perhaps by combining several *in vitro* systems including slices, and the use of tissue from liver disease patients/models.

The field of omics applied to hepatology, and to the rest of biomedical disciplines, is immense and it is difficult to ensure currency of literature and use of the most advanced techniques. Analysis at the single cell level, which are already being prototyped using fixed tissue, will transform what we know today as spatial omics. However, tissue cartography requires significant financial investment and excellent experimental design. Therefore, public-private consortiums that include basic scientists and physicians would be of great interest for the sake of advancing knowledge.

Overall, the techniques described in this review and those that are on the horizon can greatly assist to understand liver diseases, develop new therapies and foster

personalized medicine in hepatology. Of course, we need to combine them in a virtuous way, including tissue/cells of human origin whenever possible, and improving the way we mimic human diseases *in vitro*. If future work is further developed by multidisciplinary teams, success is assured.

Journal Pre-proof

Figure legends

Figure 1. Schematic view of mostly used *in vitro* models in Hepatology. PCLS, precision cut liver slices. + low; ++ medium; +++ high.

Figure 2. From single cells to liver-on-a-chip and body-on-a-chip. HSCs, hepatic stellate cells; LSECs, liver sinusoidal endothelial cells.

Figure 3. Schematic overview of *in vitro* and *ex vivo* liver models using natural scaffolds including hydrogels, fiber-like structures generated by electrospinning or bioinks (A) and synthetic scaffolds such as microporous, 3D fibrous or bioengineered platforms (B) to generate organoids/spheroids (C), PCLS and bioreactors (D), and 3D liver sinusoid on a chip (E). Natural scaffolds obtained from hepatic tissues from various sources such as human, porcine and rat undergo decellularization using detergents. Synthetic scaffolds including polymer and hydrogel based in combination with novel methods like 3D printing provides the capability for tuning the properties of the material to recreate the liver microenvironment at stages of disease progression. Current 2D and 3D hepatic models include organoids and spheroids, tissue-based approaches such as PCLS and *ex vivo* bioreactors, and liver-on-a-chip, micropatterned co-culture models. ECM, extracellular matrix; PCLS, precision cut liver slices; BEASTS, Bio-Engineered Adhesive Siloxane substrate with Tunable Stiffness.

Acknowledgements

Authors acknowledge the International Society for Hepatic Sinusoidal Research (ISHSR, www.ishsr.net) for commissioning this review article and for continuously fostering research in the field of basic and translational Hepatology.

Figures of this work were created with biorender.com

Journal Pre-proof

References

1. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet*. 2022;399(10319) :61-116.
2. Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease – A practical approach for translational research. *J Hepatol*. 2020 ;73(2):423-440.
3. Polidoro MA, Ferrari E, Marzorati S, Lleo A, Rasponi M. Experimental liver models: From cell culture techniques to microfluidic organs-on-chip. *Liver Int*. 2021;41(8):1744-1761.
4. Ortega-Ribera M, Yeste J, Villa R, Gracia-Sancho J. Nanoengineered biomaterials for the treatment of liver diseases. In: Mozafari M, Rajadas J and Kaplan D eds. *Nanoengineered Biomaterials for Regenerative Medicine*. Amsterdam, Germany: Elsevier ; 2018.p417-441.
5. Shroff T, Aina K, Maass C, Cipriano M, Lambrecht J, Tacke F, Mosig A, Loskill P. Studying metabolism with multi-organ chips: New tools for disease modelling, pharmacokinetics and pharmacodynamics. *Open Biol*. 2022;12(3) :210333.
6. Hassan S, Sebastian S, Maharjan S, Lesha A, Carpenter AM, Liu X, Xie X, Livermore C, Zhang YS, Zarrinpar A. Liver-on-a-Chip Models of Fatty Liver Disease. *Hepatology*. 2020;71(2) :733-740.
7. Du K, Li S, Li C, Li P, Miao C, Luo T, Qiu B, Ding W. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. *Acta Biomater*. 2021;134: 228-239.

8. Teng Y, Zhao Z, Tasnim F, Huang X, Yu H. A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. *Biomaterials*. 2021;275 :120904.
9. Wang Y, Wang H, Deng P, Tao T, Liu H, Wu S, Chen W, Qin J. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System. *ACS Biomater Sci Eng*. 2020;6(10):5734-5743.
10. Lefere S, Puengel T, Hundertmark J, Penners C, Frank AK, Guillot A, de Muynck K, Heymann F, Adarbes V, Defrêne E, Estivalet C, Geerts A, Devisscher L, Wettstein G, Tacke F. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. *J Hepatol*. 2020;73(4) :757-770.
11. Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. *J Hepatol*. 2021;74(5):1188-1199.
12. Deng J, Chen Z, Zhang X, Luo Y, Wu Z, Lu Y, Liu T, Zhao W, Lin B. A liver-chip-based alcoholic liver disease model featuring multi-non-parenchymal cells. *Biomed Microdevices*. 2019. ;21(3):57.
13. Lee J, Choi B, No DY, Lee G, Lee SR, Oh H, Lee SH. A 3D alcoholic liver disease model on a chip. *Integr Biol (United Kingdom)*. 2016; 8(3):302-8.
14. Nawroth JC, Petropolis DB, Manatakis DV., Maulana TI, Burchett G, Schlünder K, Witt A, Shukla A, Kodella K, Ronxhi J, Kulkarni G, Hamilton G, Seki E, Lu S, Karalis KC. Modeling alcohol-associated liver disease in a human Liver-Chip. *Cell Rep*. 2021;36(3): 109393.
15. Ortega-Prieto AM, Skelton JK, Wai SN, Large E, Lussignol M, Vizcay-Barrena G, Hughes D, Fleck RA, Thursz M, Catanese MT, Dorner M. 3D microfluidic liver cultures

as a physiological preclinical tool for hepatitis B virus infection. *Nat Commun.* 2018; 9(1):682.

16. Ortega-Ribera M, Fernández-Iglesias A, Illa X, Moya A, Molina V, Maeso-Díaz R, Fondevila C, Peralta C, Bosch J, Villa R, Gracia-Sancho J. Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications. *Biotechnol Bioeng.* 2018 ;115(10):2585-2594.

17. Fernandez-Iglesias A, Ortega Ribera M, Guixé-Muntet S, Gracia-Sancho J. 4 in 1: Antibody-free protocol for isolating the main hepatic cells from healthy and cirrhotic single rat livers. *J Cell Mol Med.* 2019 ;23(2):877-886.

18. Du Y, Khandekar G, Llewellyn J, Polacheck W, Chen CS, Wells RG. A Bile Duct-on-a-Chip With Organ-Level Functions. *Hepatology.* 2020 ;71(4):1350-1363.

19. Ya S, Ding Wg, Li S, Du K, Zhang Y, Li C, Liu J, Li F, Li P, Luo T, He L, Xu A, Gao D, Qiu B. On-Chip Construction of Liver Lobules with Self-Assembled Perfusable Hepatic Sinusoid Networks. *ACS Appl Mater Interfaces.* 2021 ;13(28):32640-32652.

20. Kang YBA, Eo J, Mert S, Yarmush ML, Usta OB. Metabolic Patterning on a Chip: Towards in vitro Liver Zonation of Primary Rat and Human Hepatocytes. *Sci Rep.* 2018 ;8(1):8951.

21. Du Y, Li N, Yang H, Luo C, Gong Y, Tong C, Gao Y, Lü S, Long M. Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip. *Lab Chip.* 2017 ;17(5):782-794.

22. Jang KJ, Otieno MA, Ronxhi, J, Lim HK, Ewart L, Kodella KR., Petropolis DB., Kulkarni G, Rubins JE, Conegliano D, Nawroth, J, Simic D, Lam W, Singer M, Barale, E, Singh B, Sonee M, Streeter AJ, Manthey C, Jones B, Srivastava A, Andersson LC, Williams, D Park, H Barrile, R Sliz, J Herland, A Haney S, Karalis K, Ingber DE. Hamilton,

- GA.Reproducing human and cross-species drug toxicities using a Liver-Chip. *Sci Sci Transl Med.* 2019 ;11(517):eaax5516.
23. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. In: *The Lancet.* Vol 383. ; 2014:1749-1761.
24. Theobald J, Ghanem A, Wallisch P, Banaeiyan AA, Andrade-Navarro MA, Taškova K, Haltmeier M, Kurtz A, Becker H, Reuter St, Mrowka R, Cheng X, Wölfl S. Liver-Kidney-on-Chip to Study Toxicity of Drug Metabolites. *ACS Biomater Sci Eng.* 2018 ;4(1):78-89.
25. De Gregorio V, Telesco M, Corrado B, Rosiello V, Urciuolo F, Netti PA, Imperato G. Intestine-Liver Axis On-Chip Reveals the Intestinal Protective Role on Hepatic Damage by Emulating Ethanol First-Pass Metabolism. *Front Bioeng Biotechnol.* 2020;8:163.
26. Wogram E, Svoboda D, Communal C, Omer A, Lungjangwa T, Sphabmixay P, Velazquez J, Schneider K, Wright CW, Mildrum S, Hendricks A, Levine S, Muffat J, Lee MJ, Lauffenburger DA., Trumper D, Jaenisch R, Griffith LG. Human physiomimetic model integrating microphysiological systems of the gut, liver, and brain for studies of neurodegenerative diseases. *Sci Adv.* 2021;7(5) :eabd1707.
27. Kim J, Lee C, Kim I, Ro J, Kim J, Min Y, Park J Sunkara V, Park YS, Michael I, Kim YA, Lee HJ, Cho YK. Three-dimensional human liver-chip emulating premetastatic niche formation by breast cancer-derived extracellular vesicles. *ACS Nano.* 2020;14(11):14971-14788.
28. Dunn JCY, Tompkins RG, Yarmush ML. Hepatocytes in collagen sandwich: Evidence for transcriptional and translational regulation. *J Cell Biol.* 1992;116(4) :1043-53.

29. Arteel GE, Naba A. The liver matrisome – looking beyond collagens. *JHEP Reports*. 2020;2(4):100115.
30. Chen W, Desert R, Ge X, Han H, Song Z, Das S, Athavale D, You H, Nieto N. The Matrisome Genes From Hepatitis B–Related Hepatocellular Carcinoma Unveiled. *Hepatol Commun*. 2021;5(9) :1571-1585.
31. Kaur S, Tripathi DM, Venugopal JR, Ramakrishna S. Advances in biomaterials for hepatic tissue engineering. *Curr Opin Biomed Eng*. 2020;13:190-196.
32. Brown JH, Das P, DiVito MD, Ivancic D, Tan LP, Wertheim JA. Nanofibrous PLGA electrospun scaffolds modified with type I collagen influence hepatocyte function and support viability in vitro. *Acta Biomater*. 2018;73 :217-227.
33. Das P, DiVito MD, Wertheim JA, Tan LP. Collagen-I and fibronectin modified three-dimensional electrospun PLGA scaffolds for long-term in vitro maintenance of functional hepatocytes. *Mater Sci Eng C*. 2020 ;111:110723.
34. Janani G, Nandi Samit K, Mandal Biman B. Functional hepatocyte clusters on bioactive blend silk matrices towards generating bioartificial liver constructs. *Acta Biomater*. 2018;67:167-182.
35. Bartneck M, Topuz F, Tag CG, Sauer-Lehnen S, Warzecha KT, Trautwein C, Weiskirchen R, Tacke F. Molecular response of liver sinusoidal endothelial cells on hydrogels. *Mater Sci Eng C*. 2015;51 :64-72.
36. Lou R, Xie H, Zheng H, Ren Y, Gao M, Guo X, Song Y, Yu W, Liu X, Ma X. Alginate-based microcapsules with galactosylated chitosan internal for primary hepatocyte applications. *Int J Biol Macromol*. 2016 ;93(Pt A):1133-1140.
37. Kidambi S, Yarmush RS, Novik Er, Chao P, Yarmush ML, Nahmias Y. Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. *Proc Natl Acad Sci U S A*. 2009;106(37) :15714-9.

38. Kidambi S, Sheng L, Yarmush ML, Toner M, Lee I, Chan C. Patterned co-culture of primary hepatocytes and fibroblasts using polyelectrolyte multilayer templates. *Macromol Biosci.* 2007;7(3) :344-53.
39. Kidambi S, Lee I, Chan C. Controlling primary hepatocyte adhesion and spreading on protein-free polyelectrolyte multilayer films. *J Am Chem Soc.* 2004;126(50) :16286-7.
40. You J, Park SA, Shin DS, Patel D, Raghunathan VK, Kim M, Murphy C J, Tae G, Revzin A. Characterizing the effects of heparin gel stiffness on function of primary hepatocytes. *Tissue Eng - Part A.* 2013;19(23-24) :2655-63.
41. Chen AA, Khetani SR, Lee S, Bhatia SN, Van Vliet KJ. Modulation of hepatocyte phenotype in vitro via chemomechanical tuning of polyelectrolyte multilayers. *Biomaterials.* 2009 ;30(6):1113-20.
42. Semler EJ, Lancin PA, Dasgupta A, Moghe PrV. Engineering hepatocellular morphogenesis and function via ligand-presenting hydrogels with graded mechanical compliance. *Biotechnol Bioeng.* 2005;89(3) :296-307.
43. Desai SS, Tung JC, Zhou VX, Grenert JP, Malato Y, Rezvani M, Español-Suñer R, Willenbring H, Weaver VM, Chang TT. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha. *Hepatology.* 2016; 64(1):261-75.
44. Natarajan V, Moeun Y, Kidambi S. Exploring interactions between primary hepatocytes and non-parenchymal cells on physiological and pathological liver stiffness. *Biology (Basel).* 2021;10(5) :408.
45. Kidambi S. Stiffness and Hepatocytes Function in Vitro.; In *Liver elastography* 2020. p645-660.

46. Natarajan V, Moeller M, Casey CA, Harris Edward N. Matrix Stiffness Regulates Liver Sinusoidal Endothelial Cell Function Mimicking Responses in Fatty Liver Disease. *bioRxiv*. 2020:2020.01.27.921353.
47. Ganesan M, Dagur RS, Makarov E, Poluektova LI, Kidambi S, Osna NA. Matrix stiffness regulate apoptotic cell death in HIV-HCV co-infected hepatocytes: Importance for liver fibrosis progression. *Biochem Biophys Res Commun*. 2018 ;500(3):717-722.
48. Natarajan V, Berglund EJ, Chen DX and Kidambi S. Substrate stiffness regulates primary hepatocyte functions. *RSC Adv*. 2015;5:80956-80966.
49. Kim Y, Kang K, Jeong J, Paik SS, Kim JS, Park SA, Kim WD, Park J, Choi D. Three-dimensional (3D) printing of mouse primary hepatocytes to generate 3D hepatic structure. *Ann Surg Treat Res*. 2017;92(2) :67-72.
50. Yang H, Sun L, Pang YH, Dandan X, Haifeng M, Shuangshuang P, Wenbo W, Yanan X, Yiyao Z, Yong C, Du S, Zhao H, Chi T, Lu X, Sang X, Zhong S, Wang X, Zhang H, Huang P, Sun W, Mao Y. Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure. *Gut*. 2021;70(3) :567-574.
51. Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, Roth B. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. *PLoS One*. 2016 ;11(7):e0158674.
52. Sharma A, Rawal P, Tripathi DM, Alodiya D, Sarin SK, Kaur S, Ghosh S. Upgrading hepatic differentiation and functions on 3d printed silk-decellularized liver hybrid scaffolds. *ACS Biomater Sci Eng*. 2021;7(8) :3861-3873.
53. Lee H, Chae S, Kim JY, Han W, Kim J, Choi Y, Cho DW. Cell-printed 3D liver-on-a-chip possessing a liver microenvironment and biliary system. *Biofabrication*. 2019;11(2) :025001.

54. Lee H, Han W, Kim H, Ha DH, Jang J, Kim BS, Cho DW. Development of Liver Decellularized Extracellular Matrix Bioink for Three-Dimensional Cell Printing-Based Liver Tissue Engineering. *Biomacromolecules*. 2017;18(4) :1229-1237.
55. Rawal P, Tripathi DM, Ramakrishna S, Kaur S. Prospects for 3D bioprinting of organoids. *Bio-Design Manuf*. 2021;4(3):627-640.
56. Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, Chen Z. Modeling physiological events in 2D vs. 3D cell culture. *Physiology*. 2017;32(4) :266-277.
57. Ramaiahgari SC, Den Braver MW, Herpers B, Terpstra V, Commandeur JNM, Van De Water B, Price LS. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. *Arch Toxicol*. 2014;88(5) :1083-95.
58. Sato K, Zhang W, Safarikia S, Isidan A, Chen AM, Li P, Francis H, Kennedy L, Baiocchi L, Alvaro D, Glaser S, Ekser B, Alpini G. Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma. *Hepatology*. 2021;74(1) :491-502.
59. Takebe T, Zhang RR, Koike H, Kimura M, Yoshizawa E, Enomura M, Koike N, Sekine K, Taniguchi H. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nat Protoc*. 2014;9(2) :396-409.
60. Sekine K, Takebe T, Taniguchi H. Liver regeneration using cultured liver bud. *Methods in Molecular Biology*. 2017;1597:207-216.
61. Takebe T, Sekine K, Kimura M, Yoshizawa E, Ayano S, Koido M, Funayama S, Nakanishi N, Hisai T, Kobayashi T, Kasai T, Kitada R, Mori A, Ayabe H, Ejiri Y, Amimoto N, Yamazaki Y, Ogawa S, Ishikawa M, Kiyota Y, Sato Y, Nozawa K, Okamoto S, Ueno Y, Taniguchi H. Massive and Reproducible Production of Liver Buds Entirely from Human Pluripotent Stem Cells. *Cell Rep*. 2017;21(10) :2661-2670.

62. Achilli TM, Meyer J, Morgan JR. Advances in the formation, use and understanding of multi-cellular spheroids. *Expert Opin Biol Ther.* 2012;12(10) :1347-60.
63. Huch M, Koo BK. Modeling mouse and human development using organoid cultures. *Dev.* 2015;142(18) :3113-25.
64. Hong S, Song JM. A 3D cell printing-fabricated HepG2 liver spheroid model for high-content in situ quantification of drug-induced liver toxicity. *Biomater Sci.* 2021;9(17) :5939-5950.
65. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature.* 2013;499(7459).
66. Camp JG, Sekine K, Gerber T, Loeffler-Wirth H, Binder H, Gac M, Kanton S, Kageyama J, Damm G, Seehofer D, Belicova L, Bickle M, Barsacchi R, Okuda R, Yoshizawa E, Kimura M, Ayabe H, Hideki T, Takebe T, Treutlein B. *Nature.* 2017 ;546(7659):533-538.
67. Shinozawa T, Kimura M, Cai Y, Saiki N, Yoneyama Y, Ouchi R, Koike H, Maezawa M, Zhang RR, Dunn A, Ferguson A, Togo S, Lewis K, Thompson WL, Asai A, Takebe T. High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids. *Gastroenterology.* 2021;160(3) :831-846.e10.
68. Ouchi R, Togo S, Kimura M, Shinozawa T, Koido M, Koike H, Thompson W, Karns RA., Mayhew CN., McGrath PS., McCauley HA., Zhang RR, Lewis K, Hakozaaki S, Ferguson A, Saiki N, Yoneyama Y, Takeuchi I, Mabuchi Y, Akazawa C, Yoshikawa HY, Wells JM, Takebe T. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids. *Cell Metab.* 2019;30(2) :374-384.e6.
69. Hendriks D, Artegiani B, Hu H, Chuva de Sousa Lopes S, Clevers H. Establishment of human fetal hepatocyte organoids and CRISPR–Cas9-based gene

knockin and knockout in organoid cultures from human liver. *Nat Protoc.* 2021;16(1):182-217.

70. Sampaziotis F, Muraro D, Tysoe OC, Sawiak S, Beach TE, Godfrey EM, Upponi SS., Brevini T, Wesley BT, Garcia-Bernardo J, Mahbubani K, Canu G, Gieseck R, Berntsen NL, Mulcahy VL, Crick K, Fear C, Robinson S, Swift L, Gambardella L, Bargehr J, Ortmann D, Brown SE, Osnato A, Murphy MP, Corbett G, Gelson WTH, Mells GF, Humphreys P, Davies SE, Amin I, Gibbs P, Sinha S, Teichmann SA., Butler AJ, See TC, Melum E, Watson CE, Saeb-Parsy K, Vallier L. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. *Science.* 2021 ;371(6531):839-846.

71. Roos, FJ M, van Tienderen, GS, Wu, H, Bordeu, I, Vinke, D, Albarinos, L Muñoz, Monfils, Ka, Niesten, S, Smits, R, Willemse, J, Rosmark, O, Westergren-Thorsson, G, Kunz, DJ, de Wit, M, French, P, Vallier, L, IJzermans, JNM, Bartfai, R, Marks, H, Simons, BD, van Royen ME, Verstegen, MMA, van der Laan, LJW. Human branching cholangiocyte organoids recapitulate functional bile duct formation. *Cell Stem Cell.* 2022;29(5):776-794.e13.

72. Guan Y, Xu D, Garfin PM, Ehmer U, Hurwitz M, Enns G, Michie S, Wu M, Zheng M, Nishimura T, Sage J, Peltz G. Human hepatic organoids for the analysis of human genetic diseases. *JCI Insight.* 2017;2(17) :e94954.

73. Ogawa M, Ogawa S, Bear CE, Ahmadi S, Chin S, Li B, Grompe M, Keller G, Kamath BM, Ghanekar A. Directed differentiation of cholangiocytes from human pluripotent stem cells. *Nat Biotechnol.* 2015;33(8) :853-61.

74. Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. *Hepatology.* 2019;70(3) :871-882.

75. Nantasanti S, Spee B, Kruitwagen HS, Chen C, Geijsen N, Oosterhoff LA., Van Wolferen ME., Pelaez N, Fieten H, Wubbolts RW., Grinwis GC, Chan J, Huch M, Vries

RR.G., Clevers H, De Bruin A, Rothuizen J, Penning LC, Schotanus BA. Disease modeling and gene therapy of copper storage disease in canine hepatic organoids. *Stem Cell Reports*. 2015;5(5) :895-907.

76. Nie YZ, Zheng YW, Miyakawa K, Murata S, Zhang RR, Sekine K, Ueno Y, Takebe T, Wakita T, Ryo A, Taniguchi H. Recapitulation of hepatitis B virus–host interactions in liver organoids from human induced pluripotent stem cells. *EBioMedicine*. 2018;35 :114-123.

77. Kruitwagen HS, Oosterhoff LA, Vernooij IGWH, Schrall IM, van Wolferen ME, Bannink F, Roesch C, van Uden L, Molenaar MR, Helms JB, Grinwis GCM, Verstegen MMA., van der Laan LJW, Huch M, Geijssen N, Vries RG, Clevers H, Rothuizen J, Schotanus BA, Penning LC, Spee B. Long-Term Adult Feline Liver Organoid Cultures for Disease Modeling of Hepatic Steatosis. *Stem Cell Reports*. 2017;8(4) :822-830.

78. Broutier L, Mastrogiovanni G, Verstegen MMA, Francies HE, Gavarró L Morrill Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP, Georgakopoulos N, Koo Bon K, Dietmann S, Davies SE, Praseedom RK, Lieshout R, IJzermans JNM, Wigmore SJ, Saeb-Parsy K, Garnett MJ, Van Der Laan LJW, Huch M. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. *Nat Med*. 2017;23(12) :1424-1435.

79. De Graaf IAM, Olinga P, De Jager MH, Merema MT, De Kanter R, Van De Kerkhof EG, Groothuis GMM. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. *Nat Protoc*. 2010;5(9) :1540-51.

80. Dewyse L, Reynaert H, van Grunsven LA. Best practices and progress in precision-cut liver slice cultures. *Int J Mol Sci*. 2021;22(13) :7137.

81. Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, Massault PP, Scatton O, Vaillant JC, Morozov VA, Pol S, Lagaye S. Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs. *World J Hepatol.* 2021;13(2) :187-217.
82. Koch A, Saran S, Tran D, Klebba-Färber S, Thiesler H, Sewald K, Schindler S, Braun A, Klopffleisch R, Tamura T. Murine precision-cut liver slices (PCLS): a new tool for studying tumor microenvironments and cell signaling ex vivo. *Cell Commun Signal.* 2014; 7;12:73.
83. Paish HL, Reed LH, Brown H, Bryan MC, Govaere O, Leslie J, Barksby BS, Garcia M, Marina W, Abigail X, Xin Z, Marco YW, Greaves L, Whitehall J, French J, White SA., Manas DM, Robinson SM, Spoletini G, Griffiths C, Mann DA, Borthwick LA, Drinnan MJ, Mann J, Oakley F. A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision-Cut Liver Slices. *Hepatology.* 2019;70(4) :1377-1391.
84. Wu X, Roberto JB, Knupp A, Kenerson HL, Truong CD, Yuen SY, Brempele KJ, Tuefferd M, Chen A, Horton H, Yeung RS, Crispe IN. Precision-cut human liver slice cultures as an immunological platform. *J Immunol Methods.* 2018;455 :71-79.
85. Lang R, Stern MM, Smith L, Liu Y, Bharadwaj S, Liu G, Baptista PM, Bergman CR, Soker S, Yoo JJ, Atala A, Zhang Y. Three-dimensional culture of hepatocytes on porcine liver tissue-derived extracellular matrix. *Biomaterials.* 2011;32(29) :7042-52.
86. Schneeberger, K, Sánchez-Romero, N, Ye, S, van Steenbeek, FG., Oosterhoff, LA., Pla P, Iris, CC, van Wolferen, ME., van Tienderen, G, Lieshout, R, Colemonts-Vroninks, H, Schene, I, Hoekstra, R, Verstegen, MM.A., van der Laan, LJ.W., Penning, LC., Fuchs, SA., Clevers, H, De Kock, J, Baptista, PM., Spee, B. Large-Scale Production of LGR5-Positive Bipotential Human Liver Stem Cells. *Hepatology.* 2020;72(1) :257-270.
87. Othman A, Ehnert S, Dropmann A, Ruoß M, Nüssler AK, Hammad S. Precision-cut liver slices as an alternative method for long-term hepatotoxicity studies. *Arch Toxicol.* 2020;94(8) :2889-2891.

88. Bigaeva E, Gore E, Simon E, Zwick M, Oldenburger A, de Jong KP, Hofker HS, Schlepütz M, Nicklin P, Boersema M, Rippmann JF, Olinga P. Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. *Arch Toxicol*. 2019;93(12) :3549-3583.
89. Brugger M, Laschinger M, Lampl S, Schneider A, Manske K, Esfandyari D, Hüser N, Hartmann D, Steiger K, Engelhardt S, Wohlleber D, Knolle PA. High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment. *JHEP Reports*. 2022;4(5) :100465.
90. Dubray BJ, Conzen KD, Upadhya GA, Balachandran P, Jia J, Knolhoff BL, Alpers DH, Mohanakumar T, Chapman WC, Anderson CD. Novel in vitro model for studying hepatic ischemia-reperfusion injury using liver cubes. *Surg (United States)*. 2012;152(2) :247-53.
91. Gracia-Sancho J, Marrone G, Fernández-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. *Nat Rev Gastroenterol Hepatol*. 2019. ;16(4):221-234.
92. Gracia-Sancho J, Caparrós E, Fernández-Iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. *Nat Rev Gastroenterol Hepatol*. 2021 ;18(6):411-431.
93. Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. *Circ Res*. 1996;78(5) :750-8.
94. Kang N. Mechanotransduction in Liver Diseases. *Semin Liver Dis*. 2020;40(1) :84-90.
95. Mueller S. Does pressure cause liver cirrhosis? the sinusoidal pressure hypothesis. *World J Gastroenterol*. 2016 ;22(48):10482-10501

96. Piecha F, Peccerella T, Bruckner T, Seitz Helmut K, Rausch V, Mueller S. Arterial pressure suffices to increase liver stiffness. *Am J Physiol - Gastrointest Liver Physiol*. 2016;311(5):G945-G953.
97. Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. *J Clin Invest*. 1997;100(11):2923-2930.
98. Gracia-Sancho J, Russo L, García-Calderó H, García-Pagán JC, García-Cardena G, Bosch J. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. *Gut*. 2011;60(4):517-524.
99. Hilscher MB, Sehrawat T, Arab JP, Zeng Z, Gao J, Liu M, Kostallari E, Gao Y, Simonetto DA, Yaqoob U, Cao S, Revzin A, Beyder A, Wang RA, Kamath PS, Kubes P, Shah VH. Mechanical Stretch Increases Expression of CXCL1 in Liver Sinusoidal Endothelial Cells to Recruit Neutrophils, Generate Sinusoidal Microthrombi, and Promote Portal Hypertension. *Gastroenterology*. 2019. ;157(1):193-209.e9.
100. Ortega-Ribera M, Gibert-Ramos A, Abad-Jordà L, Magaz M, De Souza B, Olivas P, Orts L, Lozano JJ, Villa R, Bosch J, García-Pagán JC, Gracia-Sancho J. Increased sinusoidal pressure influences LSEC mechanosensing pathways uncovering specific plasma biomarkers of portal hypertension. *Hepatology* 2021;74(S1):157-1288.
101. Liu L, You Z, Yu H, Zhou L, Zhao H, Yan X, Li D, Wang B, Zhu L, Xu Y, Xia T, Shi Y, Huang C, Hou W, Du Y. Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis. *Nat Mater*. 2017;16(12):1252-1261.
102. Olsen L, Bloomer SA, Chan EP, Gaça MDA, Georges PC, Sackey B, Uemura M, Janmey PA, Wells RG. Hepatic stellate cells require a stiff environment for

myofibroblastic differentiation. *Am J Physiol - Gastrointest Liver Physiol.* 2011 ;301(1):G110-8.

103. Juin A, Planus E, Guillemot F, Horakova P, Albiges-Rizo C, Génot E, Rosenbaum J, Moreau V, Saltel F. Extracellular matrix rigidity controls podosome induction in microvascular endothelial cells. *Biol Cell.* 2013;105(1) :46-57.

104. Dou C, Liu Z, Tu K, Zhang H, Chen C, Yaqoob U, Wang Y, Wen J, van Deursen J, Sicard D, Tschumperlin D, Zou H, Huang WC, Urrutia R, Shah VH, Kang N. P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts. *Gastroenterology.*2018 ;154(8):2209-2221.e14.

105. Guixé-Muntet, S., Ortega-Ribera, M., Wang, C., Selicean, S., Andreu, I., Kechagia J.Z., Fondevila, C., Roca-Cusachs, P., Dufour, J. F., Bosch, J., Berzigotti, A & Gracia-Sancho J. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. *J HEP Rep.* 2020 ;2(5):100145.

106. Baselli Guido A, Dongiovanni P, Rametta R, Meroni M, Pelusi S, Maggioni M, Badiali S, Pingitore P, Maurotti S, Montalcini T, Taliento AE, Prati D, Rossi G, Fracanzani AL, Mancina RM, Romeo S, Valenti L. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. *Gut.* 2020;69(10) :1855-1866.

107. Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. *Sci Transl Med.* 2022;14(650):eabo4474.

108. Liu Chang, Ampuero J, Gil-Gómez A, Montero-Vallejo R, Rojas Á, Muñoz-Hernández R, Gallego-Durán R, Romero-Gómez M. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J Hepatol*. 2018;69(6) :1335-1348.
109. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis. *Gut*. 2015;64(5) :800-12.
110. Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, Chandhoke V, Younossi ZM. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2010;32(3) :487-97.
111. Manicardi N, Fernández-Iglesias A, Abad-Jordà L, Royo F, Azkargorta M, Ortega-Ribera M, Sanfeliu-Redondo D, Martínez-Alcocer A, Elortza F, Hessheimer AJ, Fondevila C, Lozano JJ, García-Pagán JC, Bosch J, Cubero FJ, Albillos A, Vaquero J, Falcón-Pérez JM, Gracia-Sancho J. Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. *Cancers (Basel)*. 2021 ;13(11):2688.
112. Krahmer N, Najafi B, Schueder F, Quagliarini F, Steger M, Seitz S, Kasper R, Salinas F, Cox J, Uhlenhaut NH, Walther TC, Jungmann R, Zeigerer A, Borner G, Heinz H, Mann M. Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in Diet-Induced Hepatic Steatosis. *Dev Cell*. 2018;47(2) :205-221.e7.
113. Yuan X, Sun Y, Cheng Q, Hu K, Ye J, Zhao Y, Wu J, Shao X, Fang L, Ding Y, Sun X, Shi X, Xue B. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease. *J Proteomics*. 2020; 221:103683.

114. Vu LT, Orbach SM, Ray WK, Cassin ME, Rajagopalan P, Helm RF. The hepatocyte proteome in organotypic rat liver models and the influence of the local microenvironment. *Proteome Sci.* 2017;15:12.
115. Lao Y, Li Y, Hou Y, Chen H, Qiu B, Lin W, Sun A, Wei H, Jiang Y, He F. Proteomic Analysis Reveals Dab2 Mediated Receptor Endocytosis Promotes Liver Sinusoidal Endothelial Cell Dedifferentiation. *Sci Rep.* 2017;7(1) :13456.
116. Deleve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. *Hepatology.* 2015;61(5):1740-1746.
117. Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The hepatic sinusoid in chronic liver disease: The optimal milieu for cancer. *Cancers (Basel).* 2021;13(22) :5719.
118. Kim Su R, Kubo T, Kuroda Y, Hojyo M, Matsuo T, Miyajima A, Usami M, Sekino Yuko, Matsushita T, Ishida S. Comparative metabolome analysis of cultured fetal and adult hepatocytes in humans. *J Toxicol Sci.* 2014;39(5) :717-23.
119. Li H, Zhu W, Zhang L, Lei H, Wu X, Guo L, Chen X, Wang Y, Tang H. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. *Sci Rep.* 2015;5 :8421.
120. Yue D, Zhang Y, Cheng L, Ma J, Xi Y, Yang L, Su C, Shao B, Huang A, Xiang R, Cheng P. Hepatitis B virus X protein (HBx)-induced abnormalities of nucleic acid metabolism revealed by ¹H-NMR-based metabolomics. *Sci Rep.* 2016;6 :24430.
121. Min Hae K, Sookoian S, Pirola CJ, Cheng J, Mirshahi F, Sanyal AJ. Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells. *Am J Physiol - Gastrointest Liver Physiol.* 2014;307(1) :G66-76.

122. Martínez-Arranz I, Bruzzzone C, Nouredin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. *Hepatology*. Published online 2022.
123. Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavín Trueba JL, Mayo R, Ilisso CP, de Juan VG, Iruarrizaga-Lejarreta M, delaCruz-Villar L, Mincholé I, Robinson A, Crespo J, Martín-Duce A, Romero-Gómez M, Sann H, Platon J, Van Eyk J, Aspichueta P, Nouredin M, Falcón-Pérez JM, Anguita J, Aransay AM, Martínez-Chantar ML, Lu SC, Mato JM. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. *Gastroenterology*. 2017; 152(6):1449-1461.
124. Saliba Antoine E, Westermann AJ, Gorski SA, Vogel J. Single-cell RNA-seq: Advances and future challenges. *Nucleic Acids Res*. 2014;42(14) :8845-60.
125. Krenkel O, Hundertmark J, Ritz T, Weiskirchen R, Tacke F. Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. *Cells*. 2019;8(5) :503.
126. Su T, Yang Y, Lai S, Jeong J, Jung Y, McConnell M, Utsumi T, Iwakiri Y. Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. *CMGH*. 2021 ;11(4):1139-1161.
127. Nault R, Fader KA, Bhattacharya S, Zacharewski TR. Single-Nuclei RNA Sequencing Assessment of the Hepatic Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin. *CMGH*. 2021;11(1) :147-159.

128. Lotto J, Drissler S, Cullum R, Wei W, Setty M, Bell EM, Boutet SC, Nowotschin S, Kuo YY, Garg V, Pe'er D, Church DM, Hadjantonakis AK, Hoodless PA. Single-Cell Transcriptomics Reveals Early Emergence of Liver Parenchymal and Non-parenchymal Cell Lineages. *Cell*. 2020;183(3) :702-716.e14..
129. Ramachandran P, Matchett KP, Dobie R, Wilson-Kanamori JR, Henderson NC. Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis. *Nat Rev Gastroenterol Hepatol*. 2020;17(8):457-472.
130. Blériot C, Barreby E, Dunsmore G, Ballaire R, Chakarov S, Ficht X, De Simone G, Andreato F, Fumagalli V, Guo W, Wan G, Gessain G, Khalilnezhad A, Zhang XM, Ang N, Chen P, Morgantini C, Azzimato V, Kong WT, Liu Z, Pai R, Lum J, Shihui F, Low I, Xu C, Malleret B, Kairi MFM, Balachander A, Cexus O, Larbi A, Lee B, Newell EW, Ng LG, Phoo WW, Sobota RM, Sharma A, Howland SW, Chen J, Bajenoff M, Yvan-Charvet L, Venteclef N, Iannacone M, Aouadi M, Ginhoux F. A subset of Kupffer cells regulates metabolism through the expression of CD36. *Immunity*. 2021; 54(9):2101-2116..
131. Remmerie A, Martens L, Thoné T, Castoldi A, Seurinck R, Pavie B, Roels J, Vanneste B, De Prijck S, Vanhockerhout M, Binte Abdul Latib M, Devisscher L, Hoorens A, Bonnardel J, Vandamme N, Kremer A, Borghgraef P, Van Vlierberghe H, Lippens S, Pearce E, Saeys Y, Scott CL. Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. *Immunity*. 2020; 53(3):641-657.
132. Seidman JS, Troutman TD, Sakai M, Gola A, Spann NJ, Bennett H, Bruni CM, Ouyang Z, Li RZ, Sun X, Vu BT, Pasillas MP, Ego KM, Gosselin D, Link VM, Chong LW, Evans RM, Thompson BM, McDonald JG, Hosseini M, Witztum JL, Germain RN, Glass CK. Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. *Immunity*. 2020; 52(6):1057-1074.

133. Tran S, Baba I, Poupel L, Dussaud S, Moreau M, G lineau A, Marcelin G, Magr eau-Davy E, Ouhachi M, Lesnik P, Boissonnas A, Le Goff W, Clausen BE, Yvan-Charvet L, Sennlaub F, Huby T, Gautier EL. Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis. *Immunity*. 2020;53(3) :627-640.e5.
134. Daemen SA, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, Liss KH, Klein S, Feldstein AE, Finck BN, Artyomov MN, Schilling JD. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. *Cell Rep*. 2021;34(2) :108626.
135. Krenkel O, Hundertmark J, Abdallah AT, Kohlhepp M, Puengel T, Roth T, Branco DPP, Mossanen JC, Luedde T, Trautwein C, Costa IG, Tacke F. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. *Gut*. 2020;69(3) :551-563.
136. Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, Lundgren P, Bleriot C, Liu Z, Deczkowska A, Keren-Shaul H, David E, Zmora N, Eldar SM, Lubezky N, Shibolet O, Hill DA, Lazar MA, Colonna M, Ginhoux F, Shapiro H, Elinav E, Amit I. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. *Cell*. 2019; 178(3):686-698..
137. Payen VL, Arnaud L, Niki Alevra S, Megan C, Latifa K, Manon D, Mustapha N, Wouter C, Beno t C, Sokal EM, Adil EIT. Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity. *JHEP Reports*. 2021. ;3(3):100278.
138. MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, Manuel J, Khuu N, Echeverri J, Linares I, Gupta R, Cheng ML, Liu LY, Camat D, Chung SW, Seliga RK, Shao Z, Lee E, Ogawa S, Ogawa M, Wilson MD, Fish JE, Selzner M, Ghanekar A, Grant D, Greig P, Sapisochin G, Selzner N, Winegarden N, Adeyi O, Keller G, Bader

GD, McGilvray ID. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. *Nat Commun.* 2018;9(1) :4383.


139. Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, Taylor RS, Efremova M, Vento-Tormo R, Carragher NO, Kendall TJ, Fallowfield JA, Harrison EM, Mole DJ, Wigmore SJ, Newsome PN, Weston CJ, Iredale JP, Tacke F, Pollard JW, Ponting CP, Marioni JC, Teichmann SA, Henderson NC. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. *Nature.* 2019 ;575(7783):512-518.






140. Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, Modak M, Carotta S, Haslinger C, Kind D, Peet GW, Zhong G, Lu S, Zhu W, Mao Y, Xiao M, Bergmann M, Hu X, Kerkar SP, Vogt AB, Pflanz S, Liu K, Peng J, Ren X, Zhang Z. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. *Cell.* 2019;179(4) :829-845.e20.

141. Saviano A, Henderson NC, Baumert TF. Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology. *J Hepatol.* 2020;73(5) :1219-1230.

142. Guillot A, Tacke F. Location, location, location — spatial insight into hepatic macrophage populations. *Nat Rev Gastroenterol Hepatol.* 2022.19(5) :281-282.

143. Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, Bujko A, Martens L, Thoné T, Browaeys R, De Ponti FF, Vanneste B, Zwicker C, Svedberg FR, Vanhalewyn T, Gonçalves A, Lippens S, Devriendt B, Cox E, Ferrero G, Wittamer V, Willaert A, Kaptein SJF, Neyts J, Dallmeier K, Geldhof P, Casaert S, Deplancke B, Ten Dijke P, Hoorens A, Vanlander A, Berrevoet F, Van Nieuwenhove Y, Saeys Y, Saelens W, Van Vlierberghe H, Devisscher L, Scott CL. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. *Cell.* 2022;185(2) :379-396.e38.



	2D cell culture	2D cell co-culture	Liver on a chip	PCLS	Organoid/spheroid
					
Accessibility	+++	+++	+	+	++
Complexity	+	+	+++	++	+++
Reproducibility	+++	+++	++	++	++
Relevance	+	++	+++	+++	+++
Human-derived	Primary cells	Primary cells	Primary cells	Fresh tissue	Human-like cells
Biomechanical stimuli	Stiffness	Stiffness (bottom well)	Stiffness, controlled shear stress, pressure	Intrinsic matrix stiffness	Stiffness, perfusion

